Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
News and Events

Featured Stories

Hot information:
Top 10 Global CDMO Enterprises| Top 10 Global Clinical Research Organizations in 2021| The Meaning of IND, NDA and ANDA
Jan 05,2023
The Role of the Ames Test in Predicting the Genotoxicity of Impurity Compounds in Drugs
The Ames test is short-term in vitro test method for preliminary screening of the mutagenicity of chemical substances by using the properties of the reverse mutation of the histidine auxotrophic mutant strain of Salmonella typhimurium.
More
The Role of the Ames Test in Predicting the Genotoxicity of Impurity Compounds in Drugs
Jan 02,2023
​Aim at chemical synthesis through Ibuprofen
The synthesis of Ibuprofen starts from isobutyl benzene. The synthesis procedure includes Friedel-Crafts acylation, reduction, chloride substitution, and Grignard reaction. The products of each step were then analyzed by IR and 1 H NMR spectroscopy, and the final product was confirmed by analysis of melting points.
More
​Aim at chemical synthesis through Ibuprofen
Dec 27,2022
What is Meant by Target Validation and How is Target Validation Done?
Target validation refers to the accumulation of scientific evidence that a target (usually a protein) is modulated (usually inhibited) for therapeutic use.
More
What is Meant by Target Validation and How is Target Validation Done?
Dec 26,2022
"China's Pharmaceutical CDMO Industry Map in 2021" is Coming-Echelon Ranking and Distribution
As an essential part of the new drug research and development industry, the company provides services throughout the entire life cycle of the drug, from preclinical research to clinical phase I and before the drug patent expires.
More
"China's Pharmaceutical CDMO Industry Map in 2021" is Coming-Echelon Ranking and Distribution
Dec 26,2022
CDMO Development Enters the Fast Lane
The primary source of CDMO demand is the outsourcing part of process development and experimental drug production of large and small pharmaceutical companies.
More
CDMO Development Enters the Fast Lane
Dec 23,2022
Global CDMO Catalent
Catalent, headquartered in New Jersey, has nearly 90 years of experience developing new drugs, with sales of 4 billion US dollars in 2021. The multifunctional pharmaceutical manufacturing platform in more than 50 locations worldwide provides more than 70 billion doses and 7000 million doses to more than 1,000 customers annually.
More
Global CDMO Catalent
Dec 02,2022
What is CRO,CMO,CDMO
Contract Research Organization referred to as CRO, mainly provides drug discovery, preclinical research, clinical trials, and other new drug R&D contract research services for multinational pharmaceutical companies and pharmaceutical companies. Biomedical R&D outsourcing has gradually become an indispensable link in the pharmaceutical industry chain and plays a vital role in the industrial structure.
More
What is CRO,CMO,CDMO
Oct 12,2022
Toxicity of ADC drugs
On February 3rd, Johnson & Johnson announced that it had reached a cooperation agreement with Mersana Therapeutics to jointly develop three new generation ADC drugs.
More
Toxicity of ADC drugs
Oct 11,2022
Present Situation, Challenge, Opportunity and Future of ADC
At present, a variety of antibody-coupled drugs (ADC) have been approved for the treatment of solid tumors, and have been rapidly extended to indications of multiple tumor types. For example, anti-HER2 ADC, anti-Trop-2 ADC, anti-nectin-4 ADC, etc.
More
Present Situation, Challenge, Opportunity and Future of ADC
Sep 30,2022
Medicilon Pharmacokinetic Services for First-in-Class Ubiquitination Inhibitor Development
TAK-243 was found to have significant antitumor activity. Among other things, researchers conducted in vivo efficacy experiments using the HCC-70 model through Medicilon. The results revealed a tumor growth inhibition (TGI) rate of 91%.
More
Medicilon Pharmacokinetic Services for First-in-Class Ubiquitination Inhibitor Development